NCT06793085

Brief Summary

The study will involve measurements and comparisons of the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, as well as anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress67%
Jan 2025Dec 2026

First Submitted

Initial submission to the registry

January 20, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

January 20, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 27, 2025

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

March 18, 2026

Status Verified

March 1, 2026

Enrollment Period

1.4 years

First QC Date

January 20, 2025

Last Update Submit

March 17, 2026

Conditions

Keywords

menstrual disorderschronic inflammationinsulin resistancemetabolic syndromePolycystic Ovary Syndrome

Outcome Measures

Primary Outcomes (4)

  • Il-6 concentration

    Measurement and comparison of serum interleukin-6 (il-6) concentration expressed in \[pg/ml\] in three research groups

    up to 6 months

  • Il-18 concentration

    Measurement and comparison of serum interleukin-18 (il-18) concentration expressed in \[pg/ml\] in three research groups

    up to 6 months

  • Il-4 concentration

    Measurement and comparison of serum interleukin-4 (il-4) concentration expressed in \[pg/ml\] in three research groups

    up to 6 months

  • TNF-α concentration

    Measurement and comparison of serum tumor necrosis factor α (TNF-α) concentration expressed in \[pg/ml\] in three research groups

    up to 6 months

Study Arms (3)

Polycystic ovary syndrome (PCOS)+ insulin resistance (IR)

Diagnostic Test: Measurement of interleukin-6 (il-6) concentration in blood serumDiagnostic Test: Measurement of fasting tumor necrosis factor α (TNF-α) concentrationDiagnostic Test: Measurement of interleukin-18 (il-18) concentrationDiagnostic Test: Measurement of interleukin-4 (il-4) concentration

Polycystic ovary syndrome (PCOS)+ no insulin resistance (IR)

Diagnostic Test: Measurement of interleukin-6 (il-6) concentration in blood serumDiagnostic Test: Measurement of fasting tumor necrosis factor α (TNF-α) concentrationDiagnostic Test: Measurement of interleukin-18 (il-18) concentrationDiagnostic Test: Measurement of interleukin-4 (il-4) concentration

No PCOS

Diagnostic Test: Measurement of interleukin-6 (il-6) concentration in blood serumDiagnostic Test: Measurement of fasting tumor necrosis factor α (TNF-α) concentrationDiagnostic Test: Measurement of interleukin-18 (il-18) concentrationDiagnostic Test: Measurement of interleukin-4 (il-4) concentration

Interventions

Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum

No PCOSPolycystic ovary syndrome (PCOS)+ insulin resistance (IR)Polycystic ovary syndrome (PCOS)+ no insulin resistance (IR)

Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma

No PCOSPolycystic ovary syndrome (PCOS)+ insulin resistance (IR)Polycystic ovary syndrome (PCOS)+ no insulin resistance (IR)

Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum

No PCOSPolycystic ovary syndrome (PCOS)+ insulin resistance (IR)Polycystic ovary syndrome (PCOS)+ no insulin resistance (IR)

Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum

No PCOSPolycystic ovary syndrome (PCOS)+ insulin resistance (IR)Polycystic ovary syndrome (PCOS)+ no insulin resistance (IR)

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

women aged 18-45 years, managed for menstrual irregularities, infertility or for routine check-up

You may qualify if:

  • women aged 18-45 years

You may not qualify if:

  • previous removal of at least one ovary
  • treated diabetes of any type
  • diagnosed and treated metabolic diseases
  • diagnosed and treated autoimmune diseases
  • diagnosed and treated autoinflammatory diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jagiellonian University

Krakow, Poland

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood serum samples

MeSH Terms

Conditions

Polycystic Ovary SyndromeMenstruation DisturbancesInsulin ResistanceMetabolic Syndrome

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Kazimierz Pityński, Prof., Ph.D., M.D.

    Jagiellonian University

    STUDY CHAIR

Central Study Contacts

Iwona Gawron, Ph.D., M.D.

CONTACT

Robert Jach, Prof., Ph.D., M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, MD, Principal Investigator

Study Record Dates

First Submitted

January 20, 2025

First Posted

January 27, 2025

Study Start

January 20, 2025

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

March 18, 2026

Record last verified: 2026-03

Locations